Philips to Further Roll Out RATE: AI for Early Infection Detection at U.S. Department of Defense Through Four-Year, $25 Million Contract
After successful development and pilot, groundbreaking technology using biomarkers from wearables to predict infection is set to expand within the
RATE, in advanced development, is an early detector of pre-symptomatic infection in humans. It is part of efforts to improve the readiness monitoring of active-duty personnel and has broad application in healthcare settings. The algorithm was developed as an early warning system that can reduce an individual’s downtime and aid in quickly containing the spread of disease by allowing exposed individuals to self-isolate or seek medical attention sooner.
“Our mission is to protect our troops and ensure we can quickly detect and prevent the spread of illness that can impact their wellbeing and our ability to protect our nation,” said
The first version of the RATE algorithm, developed in 2019, used large-scale data science, machine learning, and trade-space analyses across demographics and 163 different biomarkers (vital signs and laboratory measurements) from a rich Philips data set of over 36,000 cases of hospital-acquired infections to develop a risk score. The risk score worked for multiple general types of infection, including common respiratory infections like pneumococcal pneumonia. These results were published in a 2023 study in Frontiers in Medicine.
A wearable version of the algorithm, prompted by the COVID-19 pandemic, leveraged biometric data from commercial-off-the-shelf wearables to enable early detection of infection. A 2022 study published in Nature’s Scientific Reportsshowed how, in a cohort of 9,381
“Protecting the physical health and well-being of active service members is paramount,” said
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in
About the JPEO-CBRND:
View source version on businesswire.com: https://www.businesswire.com/news/home/20241029182852/en/
Tel: +1-781-879-0692
Email: silvie.casanova@philips.com
Tel: +1-781 690 3814
Email: avi.dines@philips.com
Source: Royal Philips